CompletedPhase 2NCT02562482
Trial for Safety and Immunogenicity of a Chikungunya Vaccine, VRC-CHKVLP059-00-VP, in Healthy Adults
Studying Chikungunya
Last synced from ClinicalTrials.gov
ℹ
Clinical trial records are synced from ClinicalTrials.gov through automated extraction.
Report missing dataKey facts
- Sponsor
- National Institute of Allergy and Infectious Diseases (NIAID)
- Principal Investigator
- Nicolas Rosario, MDSan Juan Hospital
- Intervention
- VRC-CHKVLP059-00-VP(biological)
- Enrollment
- 400 enrolled
- Eligibility
- 18-60 years · All sexes
- Timeline
- 2015 – 2018
Study locations (6)
- Instituto Dermatológico y Cirugía de Piel, Santo Domingo, Dominican Republic
- University Hospital of Pointe-à-Pitre, Pointe-à-Pitre, Guadeloupe
- Centres GHESKIO, Port-au-Prince, Haiti
- Centre Hospitalier Universitaire (CHU), Martinique, Fort-de-France, Martinique
- San Juan Hospital, Research Unit, Rio Piedras, Puerto Rico
- Puerto Rico Clinical and Translational Research Consortium, San Juan, Puerto Rico
Primary source
Recruitment status, site addresses, contacts, and full eligibility criteria can change between syncs. Always verify with the trial team before planning travel or treatment.
Open NCT02562482 on ClinicalTrials.govOther trials for Chikungunya
Additional recruiting or active studies for the same condition.
- RECRUITINGPHASE2, PHASE3NCT07555392A Seamless Phase II/III, Observer-blind, to Evaluate Immunogenicity and Safety of Chikungunya Virus Vaccine in Healthy Subjects 12-65Years of Age.Bharat Biotech International Limited
- ENROLLING BY INVITATIONNCT07254702Prospective Safety Cohort Study After VLA1553 Vaccination in Municipalities Selected for Participation in the VLA1553 Pilot Vaccination Strategy in BrazilValneva Austria GmbH
- ENROLLING BY INVITATIONNCT07347002Observational Study to Assess the Effectiveness of VLA1553 Vaccine in Preventing Chikungunya During a Pilot Vaccination Strategy in BrazilValneva Austria GmbH
- ACTIVE NOT RECRUITINGNCT07163845Assessment of Chikungunya Virus Seroprevalence Before VLA1553 Vaccination in the Municipalities Selected for Participation in the VLA1553 Pilot Vaccination Strategy in BrazilValneva Austria GmbH
- ENROLLING BY INVITATIONNCT07520279Xpert® Tropical Fever Test on GeneXpert® Edge X SystemCepheid
- ACTIVE NOT RECRUITINGNCT06651372The Interest of Systematic Screening for Dengue, Chikungunya, and Zika, in Malaria-negative Return TravelersUniversity Hospital, Strasbourg, France
- RECRUITINGNCT07120724Real-World Study on Chinese Medicine for Treating Chikungunya FeverGuangzhou University of Traditional Chinese Medicine
- RECRUITINGPHASE3NCT07003984A Safety and Immunogenicity Study of CHIKV VLP Vaccine in Children.Bavarian Nordic